Načítá se...
Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans
The first human gene therapy trials using recombinant adeno-associated virus (rAAV) vectors were performed in cystic fibrosis (CF) patients. Over 100 CF patients were enrolled in 5 separate trials of rAAV2-CFTR administration via nasal, endobronchial, maxillary sinus, and aerosol delivery. Recombina...
Uloženo v:
| Vydáno v: | Hum Gene Ther Methods |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Mary Ann Liebert, Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4834522/ https://ncbi.nlm.nih.gov/pubmed/26895204 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hgtb.2015.150 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|